> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Voucher Used on Incyte’s Opzelura
- URL: https://www.fdaweb.com/priority-voucher-used-on-incytes-opzelura/
- Published: 2024-09-10T12:00:00.000Z
- Updated: 2026-09-14T14:40:49.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5157746

*Federal Register* notice: FDA is announcing that it has approved a product redeeming a rare pediatric disease priority review voucher — Incyte’s Opzelura (ruxolitinib). The JAK inhibitor was approved 9/2021 for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 12 years of age and older. To view the notice, click [here](https://public-inspection.federalregister.gov/2024-20556.pdf?ref=fdaweb.com).